Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
What if ghosts aren't dead, Bigfoot isn't always here, and UFO encounters reveal something stranger than visitors from space? Naturalist and cryptozoologist Brittany Barbieri explores “The Bending of Time,” the provocative possibility that time slips, apparitions, cryptids and missing time may be glimpses of a reality hiding in plain sight. GUEST: Brittany Barbieri is a naturalist, cryptozoologist, field researcher and television personality who has spent more than two decades investigating the strange edges of the natural world. Featured on Discovery Channel's Lost Monster Files and host of Get Weird with Brittany Barbieri, she explores everything from elusive predators and Bigfoot to hauntings, UFOs and the tantalizing possibility that some paranormal encounters may actually involve the bending of time. LINKS: Get Weird with Brittany Barbieri podcast https://www.facebook.com/brittbarbieriofficialpage/ https://www.linkedin.com/in/brittbarbieri FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! ETHOS – Life Insurance for Any Budget The #1 no-medical-exam, instant life insurance provider. Get Covered in 10 Minutes. Up to $3 Million in Coverage. Life Insurance Made Easy. Application Times May Vary. https://www.ethos.com HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/
Newly released diary entries and internal emails obtained by Sen. Rand Paul reveal that Dr. Anthony Fauci privately sounded the alarm in 2016 after learning the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) had aerosolized Ebola in a study funded by his own institute. “What idiots,” Dr. Fauci wrote in March 2016. “This should have been a classified experiment, that never should have been done in the first place.” The documents reveal that vaccinated primates exposed to the airborne pathogen suffered severe lung inflammation – with worse outcomes than the unvaccinated. “During the course of those experiments, the DOD noticed that the animals that were vaccinated had more inflammation [in the lungs than] those who were unvaccinated,” Fauci wrote in his diary at the time. “Nonetheless, the idea that the vaccine can do harm is now causing people a great deal of concern.” “Records show NIAID was funding risky research with the Defense Department. And when the results turned problematic, Dr. Fauci argued they should have been classified,” says Sen. Rand Paul. “It is clear additional oversight is needed into what Dr. Fauci's institute was paying for long before COVID.” Peter Navarro Ph.D., the former Senior Counselor to President Trump and author of Why Fauci MUST Rot in Prison, joins Dr. Drew to break down the unsealed diary, disease weaponization, and federal gain-of-function accountability. National security expert Dr. Bradley Thayer examines Chinese Communist Party leverage and geopolitical conflict. Board-certified psychiatrist Dr. Josef Witt-Doerring returns to discuss the latest findings in the Presley Gerber investigation and new studies debunking “addictive personalities.” Peter Navarro Ph.D. served as Senior Counselor to President Trump for Trade and Manufacturing. He holds a Ph.D. in economics from Harvard University and is Professor Emeritus of Economics and Public Policy at UC–Irvine. His latest book is “Why Fauci Must ROT In Prison” available at https://amzn.to/4y0A2j0. Follow at https://x.com/RealPNavarro Bradley Thayer Ph.D. is a founding member of the Committee on the Present Danger China and co-author of “Embracing Communist China: America's Greatest Strategic Failure” and author of “America's 100 Years' War: How to Win Against Communism” available at https://amzn.to/46UrxuI. Formerly, he was a Special Governmental Employee in the Department of Homeland Security. Follow at https://x.com/bradthayer Dr. Josef Witt-Doerring is a board-certified psychiatrist and former FDA Medical Officer, now Medical Director of TaperClinic. He previously worked at Janssen Pharmaceuticals and the FDA's Division of Psychiatry, and hosts the podcast Side Effects with Dr. Josef. Follow at https://x.com/drjosefWD 「 SUPPORT OUR SPONSORS 」 • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - https://kalebnation.com • Susan Pinsky - https://x.com/firstladyoflove Content Producer • Emily Barsh - https://x.com/emilytvproducer Learn more about your ad choices. Visit megaphone.fm/adchoices
Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about NMN (Nicotinamide Mononucleotide), the anti-aging supplement everyone from celebrities to your own family members seems to be asking about. Why did it explode in popularity when its cousin NAD+ was the star just a couple of years ago? Is it truly a breakthrough for aging at the cellular level, or is it just the latest shiny wellness trend? Jenn breaks down what NMN is, why it was off limits in supplements for so long, and what to look for if you are curious. She also shares what she's noticed after months of experimenting, and why some of her clients and colleagues report a very different experience. So, is NMN worth adding to your routine, or is the hype bigger than the results? Press play to find out where Jenn lands. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/ RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramNAD Plus - WebsiteGlobal NAD Plus - WebsitePrime NMN - WebsiteGlobal Prime NMN - WebsiteNutrition Nugget: NAD Jenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, NMN Supplement, NMN, NAD+, Nicotinamide Mononucleotide, NAD+ Precursor, Anti-Aging Supplement, Healthy Aging, Longevity, Cellular Energy, Mitochondrial Function, Nicotinamide Riboside, NR Vs NMN, Spermidine, Fisetin, NMN Dosage, NAD+ Levels, Cellular Health, DNA Repair, Metabolic Health, Perimenopause, Kim Kardashian, FDA, Dietary Supplements, Antioxidants, Gut Health, Cognitive Function, Insulin Sensitivity, ATP Production, Mental Clarity, Energy Support, Weight Loss, Wellness, Supplement Quality, Aging Well, Brain Health, Inflammation, Physical Performance, Women Over 40, Youth Molecule, Best NMN Supplement Dosage For Anti-Aging, NMN Vs NAD+ Supplement Which Is Better
Backlash from white men in our society. Racism is a problem when it gets woven into a country’s institutions and society. The meaning of diversifying, white men aren’t included. Savage culture. Senator Ron Johnson won’t let covid go and wants to go after the FDA official who posted the infamous ivermectin horse tweet. How many died because of that tweet.Follow The Jesse Kelly Show on YouTube: https://www.youtube.com/@TheJesseKellyShowSee omnystudio.com/listener for privacy information.
Dan Ives is a Partner and Senior Managing Director at Yorkville Ives. In this conversation, we break down where value is building in the AI trade, Dario's warnings about AI, regulatory capture, and whether OpenAI and Anthropic are in more trouble than people realize. We also discuss the White House AI meeting, sovereign AI, the US vs China race, and his new Ives Ultra Fund.=======================Arch Public is an agentic trading platform that automates investment strategies across Stocks, Commodities, ETFs and Crypto. Whether you're rotating into AI & Gold, allocating to the S&P 500, or accumulating Bitcoin, Arch Public executes your plan 24/7 without ever taking custody of your assets or funds. Sign up today at https://www.archpublic.com, and start your FREE automated trading strategy! =======================Lava is a global platform for bitcoin financial services. Spend with Lava Card and earn up to 5% back in bitcoin with every purchase— all with no annual fee, no FX fees, and zero spread. Plus you can borrow against your bitcoin at the lowest rates, earn yield on cash, and move fiat or stablecoins globally. Get started at https://www.lava.xyz/POMP=======================This episode is brought to you by Investor Health — clinician-prescribed protocols for weight, metabolism, energy, and longevity, delivered to your door in 48–72 hours. No office visits, no referrals. Plans start at $149/mo. Learn more at http://www.InvestorHealth.com/pomp. Investor Health is a telehealth platform, not a medical provider. Compounded medications are not FDA-approved. Individual results may vary and treatment requires evaluation by a licensed provider.=======================0:00 - Intro1:12 - Where's the value in the AI trade?2:32 - Dario's AI warning & regulatory capture5:15 - Are OpenAI & Anthropic in trouble?11:04 - Trump's White House AI meeting13:51 - Open source vs closed source AI15:32 - Token price war & the Anthropic IPO22:33 - How to invest in the AI trade25:04 - Personal AI agents & consumer AI26:31 - Why tech is ignoring macro headwinds30:36 - The Ives Ultra AI Fund33:21 - Data, sovereign AI & the future of work
Psychedelics are having a moment in mental health care. Research is showing promising results for conditions including depression, treatment-resistant depression, anxiety, and PTSD. But how much do we actually know — and how much is hype? ADAA member expert and licensed psychologist Jonathan Schettino, PhD, explains how psychedelics went from being viewed primarily as illegal drugs to becoming the subject of serious clinical research. He breaks down what happens during psychedelic-assisted therapy, why standardized dosing matters, and why treatment involves much more than simply taking a psychedelic and “tripping.” Listeners will learn: how researchers control psychedelic doses in clinical trials why psychedelics aren't yet FDA-approved treatments whether psychotherapy makes psychedelic treatment more effective The research is promising, but the science isn't settled. This conversation explains what we know, what we don't know, and why the next few years could be critical for understanding the future of psychedelic-assisted mental health treatment. Listen now! This episode has been sponsored by the Anxiety and Depression Association of America (ADAA). Our guest, Dr. Jonathan Schettino, is a licensed psychologist specializing in cognitive behavioral therapy (CBT) for anxiety disorders and OCD as well as research on approaches to psychedelic-assisted psychotherapy. He received his AB in psychology from Princeton University in 2004 and his Ph.D. in clinical psychology from UCLA in 2012. He completed his predoctoral psychology internship at St. Elizabeths forensic psychiatric hospital in Washington DC and postdoctoral training in personality assessment research at Otto-Friedrich Universität in Bamberg, Germany. He owns a small private psychology practice in Baltimore and has an appointment as a research psychologist at the Center for Psychedelic and Consciousness Research at Johns Hopkins University. Our host, Gabe Howard, is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are also available directly from the author. Gabe is also the host of the "Inside Bipolar" podcast with Dr. Nicole Washington. Gabe makes his home in the suburbs of Columbus, Ohio. He lives with his supportive wife, Kendall, and a Miniature Schnauzer dog that he never wanted, but now can't imagine life without. To book Gabe for your next event or learn more about him, please visit gabehoward.com. This episode has been sponsored by the Anxiety and Depression Association of America (ADAA).
This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA approval of the latest one, lirafugratinib. LITESPARK-011 demonstrated improved PFS of lenvantinib + belzutifan vs. cabozantinib in the 2nd-line setting of advanced ccRCC. This led to a recent FDA approval. We look at the toxicity, QOL, and OS data known about this combination regimen. Download the Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Who decides which treatments you can access—and at what cost? Ways2Well founder Brigham Buhler joins Dr. Josh Axe to discuss pharmacy benefit managers, prescription pricing, and his fight for peptide access. They explore his FDA testimony, the debate over BPC-157 and GLP-1 medications, and his clinic's use of plasma exchange and ozone therapy. Learn more about your ad choices. Visit megaphone.fm/adchoices
3 takeaways from my talk with CEO Fabian Calvo - BoomRx: Keep going. Fabian hit $48M in revenue. Not fast. Not easy. But he kept going. Pick partners you like. When things get hard, you get closer, not distant. Take care of yourself first. Meditation. Fitness. Family. The oxygen mask goes on you before anyone else. --- Fabian Calvo is a longevity industry executive and pharmaceutical supply chain strategist who has built, scaled, and led multiple companies across the compounding pharmacy, API sourcing, and clinic fulfillment ecosystem. He currently serves as Interim CEO and Member of the Board at WellSync Rx, a longevity medicine and strategic sourcing company based in Los Angeles. Fabian is also Co-Founder of four interconnected ventures that span the pharmaceutical supply chain: Gatlan (2022) — A longevity medicine platform based in Los Angeles NuCare API (2023) — An active pharmaceutical ingredient sourcing company based in Orange County, California BoomRx (2024) — A pharmacy portal and technology platform for physician practices, based in Tampa, Florida ProRx Pharma (2024) — A 503B outsourcing facility based in Exton, Pennsylvania Together, these companies form an integrated infrastructure for longevity medicine from raw ingredient sourcing to compounding to clinic fulfillment — giving Fabian a rare end-to-end view of the pharmaceutical supply chain. His work extends into regulatory and policy engagement. Fabian has participated in direct discussions with FDA leadership, including meetings with Dr. Martin Makary, on issues ranging from peptide reclassification (the recent Category 2 to Category 1 transition) to the SAPIR initiative — the federal effort to reshore active pharmaceutical ingredient manufacturing to the United States. At BoomRx, Fabian is helping build what he calls "the only pharmacy portal a physician practice needs" — a technology platform that consolidates multi-pharmacy workflows into one system with flat-rate shipping to all 50 states, live tracking, access to 300+ medications (many with extended Beyond-Use Dates), and best-rate pricing. Outside of his operating roles, Fabian advises elite founders, executives, and high-net-worth individuals on longevity and performance optimization. He publishes Long Live, a weekly newsletter on the intersection of longevity, performance, and what he sees from inside the supply chain. He is based in Los Angeles County, California. Connect with Jon Dwoskin: Twitter: @jdwoskin Facebook: https://www.facebook.com/jonathan.dwoskin Instagram: https://www.instagram.com/thejondwoskinexperience/ Website: https://jondwoskin.com/LinkedIn: https://www.linkedin.com/in/jondwoskin/ Email: jon@jondwoskin.com Get Jon's Book: The Think Big Movement: Grow your business big. Very Big! Connect with Fabian Calvo: Instagram: https://www.instagram.com/fabianjcalvo LinkedIn: https://www.linkedin.com/in/fabian-calvo-875633244 *E - explicit language may be used in this podcast.
Peptides continue to gain popularity for their potential preventive and proactive health benefits. Yet as the buzz grows, so does the confusion. Emerging research touts their ability to treat injuries, optimize health, and rejuvenate the body; at the same time, questionable gray-market options and misinformation have become more prevalent. In this episode, Jim LaValle, RPh, CCN, explores the evolution of the peptide revolution. He breaks down the key differences between research peptides and for-human-use peptides, explains how FDA oversight is shifting, and shares tips for spotting credible information, prioritizing safety, and making informed choices. This episode of Life Time Talks is part of our series on Performance and Longevity with MIORA. Find the episode highlights, get related resources and view the transcript for this episode at https://experiencelife.lifetime.life/podcast/the-evolving-peptide-revolution-performance-longevity-series Have thoughts you'd like to share or topic ideas for future episodes? Email us at lttalks@lt.life — we'd love to hear from you! Follow us on Instagram: @lifetime.life The information in this podcast is intended to provide broad understanding and knowledge of healthcare topics. This information is for educational purposes only and should not be considered complete and should not be used in place of advice from your physician or healthcare provider. We recommend you consult your physician or healthcare professional before beginning or altering your personal exercise, diet or supplementation program. Life Time provides administrative, non-clinical support to MIORA as well as services and amenities related to general wellness and fitness; Life Time does not provide medical advice, diagnosis, treatment or care.
As we've noted on Raise the Line from Elsevier before, the system Americans rely on to keep vaccine recommendations grounded in science has changed in ways that many in the medical community find alarming. Our guest today, Dr. Jason Goldman, has watched this shift unfold from a closer vantage point than most in his role as liaison from the American College of Physicians (ACP) to the CDC's Advisory Committee on Immunization Practices.“The vaccine guidelines must be based on science and evidence and that doesn't change because of someone's political beliefs. We have to keep politics out of healthcare,” says Dr. Goldman, who has been a prominent voice responding to the risks resulting from these changes as well as other public health issues.This candid conversation with host Lindsey Smith also explores:Why Dr. Goldman calls himself a "dinosaur";The Medicare quirk that pits doctors against each other;His advice to students when choosing a specialty.Mentioned in this episode:American College of Physicians If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Matthew Lynn Guthrie is the award-winning director of Follow the Silenced, named Best of Festival and Best Director at the Santa Monica International Film Festival. He spent four years pulling back the curtain on a story the government worked hard to bury. Matt shares the childhood tragedy that set him on this path and the voice he heard in a hospital waiting room that he still follows today. He explains why he believes America never really won World War II, why there are family names no one is allowed to say, and the hidden finding from the famous obedience experiments that shows how one person can break the spell. The conversation moves from propaganda and engineered division to the nonphysical forces that feed on fear and the shift in consciousness that could end it all overnight.Watch Follow the Silenced, free at radicallygenuine.com---------------------------------------------------------------------------------Dr. Roger McFillin and Tracy Thurman host Radically Genuine, challenging the systems, institutions, and ideas shaping how we think, live, heal, and understand the world around us. From medicine and mental health to technology, spirituality, institutional power, and human sovereignty, Roger and Tracy question accepted narratives, challenge what others won't, and pursue truth wherever it leads.Radically Genuine is the voice of the awakening.Learn more: https://radicallygenuine.com/BUY ROGER'S BOOK: The Awakening They Cannot MedicateVISIT ROGER'S WEBSITE: https://www.drmcfillin.com/DOWNLOAD RADICALLY GENUINE PODCASTApple: https://podcasts.apple.com/us/podcast/radically-genuine/id1573253801Spotify: https://open.spotify.com/show/4D3FvCjDBW7EYv34XGBx7i?si=392b3759306a4aa8FOLLOW RADICALLY GENUINE PODCASTWebsite: https://radicallygenuine.com/YouTube: @RadicallyGenuineX (Twitter): @RadGenuineInstagram: @RadicallyGenuineShowFOLLOW ROGER & TRACYX:@DrMcFillin@TracyAThurmanInstagram & Threads-@DrMcFillin@Tracy_A_ThurmanSubstack:https://drmcfillin.substack.com
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in participants. This development highlights an increasing focus on protein-based therapies for metabolic conditions, offering new hope for tackling obesity—a major global health challenge. Similarly, Eli Lilly's Retatrutide has made headlines with its Phase 3 trial results, demonstrating a remarkable 25% body weight reduction in obese patients with type 2 diabetes. This triple agonist targets multiple receptors, marking a novel approach in metabolic therapeutics that could transform obesity and diabetes management by targeting key pathways regulating energy balance and glucose levels. In oncology, Pierre Fabre and Atara Biotherapeutics have resubmitted their Biologics License Application for Ebvallo (tabelecleucel) to the FDA. This follows successful Phase 3 trials targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a severe complication post-transplantation. If approved, tabelecleucel could provide a critical allogeneic T-cell therapy option for these patients, underscoring the evolution of cell-based therapies in cancer treatment. Regulatory news is also making waves with Segetis Therapeutics receiving FDA approval for Emcitate (tiratricol), designed to treat monocarboxylate transporter 8 deficiency. This approval is particularly significant as it marks the first U.S. treatment for this rare pediatric thyroid hormone disorder, showcasing the industry's dedication to addressing rare diseases' unmet needs. Meanwhile, artificial intelligence continues to reshape drug discovery and development processes. Collaborations such as GSK's with Wave Life Sciences on hepatic siRNA programs and Novartis Biomedical Research's partnership with CAS aim to enhance drug discovery workflows through advanced data analytics and machine learning models. In clinical trial news, Highlight Therapeutics reported successful Phase 2 results for BO-112 in high-risk head and neck basal cell carcinoma. The immunotherapy showed efficacy as an intralesional therapy, providing new hope for patients at high risk of cancer recurrence or progression. Furthermore, Amgen's Daxdilimab demonstrated positive outcomes in a Phase 2 trial for discoid lupus erythematosus by significantly reducing disease severity, highlighting interest in targeted therapies for autoimmune conditions. Connect Biopharma's Rademikibart has shown promise in reducing exacerbations of chronic obstructive pulmonary disease during its Phase 2 trial. As an IL-4/IL-13 inhibitor, it stands as a potential competitor to existing treatments like Dupixent, potentially reshaping therapeutic strategies in respiratory diseases. These advancements reflect broader trends within the pharmaceutical industry towards personalized medicine, innovative drug mechanisms, and strategic partnerships leveraging AI and advanced analytics. As these therapies progress through clinical trials and regulatory pathways, they hold promise for enhancing patient care and expanding treatment options across various disease areas. In related regulatory developments, the European Commission has revoked marketing authorization for Hansoh Pharma's Aumseqa following a legal challenge by AstraZeneca. This decision underscores the competitive nature of oncology and highlights the importance of patent disputes and regulatory compliance in maintaining market presence. On the corporate strategy front, PhRMA has appointed former House Majority Leader Eric Cantor as its CEO. This move indicates PhRMA's focus on navigating complex regulatory environments crucial for shaping healthcare policies impacting drug development and pricing. The White House is also taking steps to address global supply chain vulnerabilities by boosting domestic production of essential medicines—a strategy aimed at enhancing national security while ensuring a steady supply of critical drugs. In industry funding news, NorthStar Medical Technologies secured $185 million to advance radiopharmaceutical isotope production. With commercial-scale manufacturing of Actinium-225 completed earlier this year, NorthStar is set to significantly increase capacity by year-end—reflecting growing demand within precision medicine. In space-based innovations, Varda Space Industries raised $251 million to fuel pioneering drug manufacturing using reusable rockets in Earth's low orbit—potentially revolutionizing drug production by utilizing microgravity environments. Finally, recent developments highlight challenges within the industry as well. Companies like Novo Nordisk and BioMarin face layoffs amid evolving market demands. Meanwhile, Enanta Pharmaceuticals downsizes amid forthcoming antiviral readouts—a reflection of broader strategic pivots required to remain competitive. These developments underscore an era where scientific breakthroughs are rapidly transforming drug development paradigms. As companies navigate intellectual property challenges and strategic collaborations continue to drive innovation aimed at addressing diverse unmet medical needs across therapeutic areas, stakeholders are likely to witness continued growth and transformation in drug development and delivery paradigms worldwide. Thank you for joining us on Pharma Daily—your go-to source for insights into the ever-evolving pharmaceutical and biotech industries. Stay tuned for more updates as we continue to explore groundbreaking advancements shaping the future of medicine.Support the show
Sign up for weekly webinars: https://imahealth.org/weekly-webinars/ign up for weekly webinars: Weekly Webinars - Independent Medical Alliance What does the data show when Moderna's mRNA flu vaccine is evaluated using absolute measures of benefit and risk?IMA President and Chief Medical Officer Dr. Joseph Varon was joined by Dr. Peter McCullough, Nicolas Hulscher, and Dr. John Catanzaro to examine their new reanalysis of FDA clinical trial data for Moderna's mFLUSIVA (mRNA-1010).They discussed:• The vaccine's reported efficacy and absolute clinical benefit• Adverse reactions and reactogenicity seen in the clinical trials• Mortality findings highlighted in the authors' reanalysis• Why the authors believe the data raise unanswered questions about the vaccine's benefit-risk profile and continued licensureThe Independent Medical Alliance (formerly FLCCC) is a healthcare nonprofit on a mission to restore trust, integrity, and the doctor-patient relationship. Get involved by clicking below:• Donate: Support IMA: Donate for Advancements in Patient Care https://imahealth.org/donate/• Follow: Connect with Us - https://imahealth.org/contact/• Weekly Webinars: - https://imahealth.org/category/weekly-webinars/• Treatment Protocols: - https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/
Fascism is toxic masculinity, and the cure starts at home. Comedian, recovering Catholic and proud girl dad Pete Dominick, host of Stand Up! with Pete Dominick, turns the mic on Andrea to talk about her new book, A Reasonable Guide for Unreasonable Women: 20 Steps to Find Your Purpose and Power in a World on Fire, and how her family's Ukrainian immigrant wisdom holds the key for how we overcome a patriarchal nightmare of complicit silence and cover-ups: "when they throw you out the door, climb back in through the window." The Cornell 7 are the Epstein Class–the elite criminal impunity of male dominance destroying our planet. Andrea and Pete discuss what men can actually do, starting with Pete's rule that, "the standard you walk past is the standard you accept." They also discuss the darker truth of the "Cornell 7," the frat rapists accused of drugging and gang-raping a young woman in 2024, an investigation that has been reopened thanks to the survivor bringing a lawsuit. They also discuss why liberal blue cities may be raising the next generation of the Cornell 7/Epstein Class, and how to stop it. They cover the historical context of male dominance culture, including Christian nationalism, how women were founders of the Christian church before being pushed aside, why Mary Magdalene was arguably the first Pope and how her story–for the most part–survived 2,000 years of patriarchal revisions. They also discuss Iceland's general strike by women that ushered in a female-driven revolution, the MAGA threat against the growing psychedelics market being fast-tracked by Trump's FDA, and the divine feminine experiences widely reported at the heart of indigenous medicinal experiences, and much, much more. The world is ending. The world has always been ending. So Gaslit Nation adopts its official policy, coming soon to a t-shirt: STFU and build something. It's a rallying cry to stop doomscrolling and start planting seeds of hope and change. Progress is thanks to our unleashed creativity, defiance, and beautiful imaginations. And if you want to help us build something–a resistance to Putin–get your tax deductible ticket to Gaslit Nation and Razom's Speakeasy Benefit October 15 in New York City – you can join and be part of the festivities from anywhere: https://www.eventbrite.com/e/people-power-ukraines-unreasonable-women-tickets-2002002955733? Gaslit Nation is funded by our listeners. We could not make this show without you. Thank you to everyone who supports our independent journalism in these tough times. If you pre-order Andrea's new book and forward your receipt to GaslitNation@gmail.com, we will send you a pre-order thank you gift and a signed book plate to easily stick on to your book so that you have a signed copy. A Reasonable Guide for Unreasonable Women shows how to overcome the emotional exhaustion deliberately caused by fascist movements and turn our rage and grief into meaningful projects you and the world need. For your gift, pre-order A Reasonable Guide for Unreasonable Women from bookshop.org Show Notes Join us for a speakeasy benefit for Razom for Ukraine: https://www.eventbrite.com/e/people-power-ukraines-unreasonable-women-tickets-2002002955733? Want a plan to bash the patriarchy? Live your most creative life and help build a better world with Andrea's new book, A Reasonable Guide for Unreasonable Women: 20 Steps to Find Your Purpose and Power in a World on Fire: https://www.penguinrandomhouse.com/books/807202/a-reasonable-guide-for-unreasonable-women-by-andrea-chalupa/ Stand Up! with Pete Dominick: https://sitdownwithpete.substack.com/ Razom for Ukraine: https://www.razomforukraine.org A good overview of the Cornell 7: https://www.instagram.com/p/Dd2tYudlnHl/?img_index=1 Cornell rarely expels students in sex assault cases https://www.usatoday.com/story/news/nation/2026/09/29/cornell-sexual-assault-rape-expelled-data-exclusive/92007157007/ Frat brothers rape 300% more. One in 5 women is sexually assaulted on campus. Should we ban frats? https://www.theguardian.com/commentisfree/2014/sep/24/rape-sexual-assault-ban-frats District attorney reopens case of alleged Cornell University 'gang rape' (ABC News): https://abcnews.com/US/district-attorney-reopens-case-alleged-cornell-university-gang/story?id=136806149 New York prosecutors reopen investigation after student files lawsuit (CNN): https://www.cnn.com/2026/09/28/us/cornell-university-sexual-assault-lawsuit-hnk 50 years ago, the women of Iceland took a day off, and inspired the world (National Geographic): https://www.nationalgeographic.com/history/article/icelandic-womens-strike Vigdís Finnbogadóttir, the world's first elected female president (France 24): https://www.france24.com/en/20200731-vigdis-finnbogadottir-the-world-s-first-elected-female-president 36 Bankers, 96 Years In Jail (Reykjavík Grapevine): https://grapevine.is/news/2018/02/07/36-bankers-96-years-in-jail/ Why Only One Top Banker Went to Jail for the Financial Crisis (Better Markets): https://bettermarkets.org/newsroom/why-only-one-top-banker-went-jail-financial-crisis/ The lie that Mary Magdalene was a prostitute persisted for centuries (America Magazine): https://www.americamagazine.org/arts-culture/2024/06/28/mary-magdalene-theater-review-gospel-248254/ The Gospel of Mary of Magdala: Jesus and the First Woman Apostle, by Karen L. King (Polebridge Press): https://www.westarinstitute.org/product/the-gospel-of-mary-of-magdala Struck Down, Not Destroyed: Keeping the Faith as a Vatican Reporter, by Colleen Dulle: https://www.amazon.com/Struck-Down-Not-Destroyed-Reporter/dp/0593728424 Trump signs order fast tracking review of psychedelics for mental health (NPR): https://www.npr.org/2026/04/18/nx-s1-5789859/psychedelic-treatments-mental-health Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying podcaster (Fierce Biotech): https://www.fiercebiotech.com/biotech/trump-orders-fda-fast-track-reviews-psychedelic-drugs-after-lobbying-podcaster D. J. Taylor: Orwell's Voice (The Orwell Foundation): https://www.orwellfoundation.com/the-orwell-foundation/orwell/articles/d-j-taylor-orwells-voice/ Donald Trump Jr.'s Bahamas Wedding Was Secretly Bankrolled by a Russian Oligarch (ProPublica): https://www.propublica.org/article/donald-trump-jr-wedding-bankrolled-russian-oligarch-umar-kremlev-putin Gospel of Mary Magdalene https://www.theculturium.com/gospel-of-mary-magdalene/ The Forgotten History of Mary's Gospels https://time.com/4083110/marys-gospels/ 'The good of the world partly depends on unhistoric acts' https://www.theguardian.com/world/2020/jan/10/the-good-of-the-world-partly-depends-on-unhistoric-acts Psychedelics and the Embodied Feminine https://maps.org/news/bulletin/psychedelics-and-the-embodied-feminine/ EVENTS AT GASLIT NATION: Gaslit Nation Salons take place Mondays 4pm ET over Zoom and are recorded and shared on Patreon.com/Gaslit and GaslitNation.Substack.com for our community New! There's now a California Signal Group for Gaslit Nation listeners to find each other and connect in that state. Join on Patreon or Substack! The Gaslit Nation Outreach Committee discusses how to talk to the MAGA cult: Join on Patreon or Substack! Minnesota Signal group for Gaslit Nation listeners in the state to find each other: Join on Patreon or Substack! Vermont Signal group for Gaslit Nation listeners in the state to find each other: Join on Patreon or Substack! Arizona-based listeners launched a Signal group for others in the state to connect. Join on Patreon or Substack! Indiana-based listeners launched a Signal group for others in the state to join. Join on Patreon or Substack! Florida-based listeners are going strong meeting in person. Be sure to join their Signal group. Join on Patreon or Substack! As always, keep it kind in our chat groups, extend grace and assume good faith. A culture of care is how we build a better world.
UFOs that survive missiles. Government whistleblowers. CE5. Fatima. The Nephilim. L.A. Marzulli returns with the expanded Rungs of Disclosure, arguing we may be approaching something far bigger than extraterrestrial contact. What if the ultimate deception isn't hiding the truth about UFOs—but convincing humanity what they really are? GUEST: L.A. Marzulli is an author, filmmaker and veteran researcher exploring UFOs, ancient mysteries and biblical prophecy. His work investigates the provocative possibility that the UFO phenomenon is not simply extraterrestrial, but part of an ancient supernatural reality—and a coming deception that could challenge everything humanity believes about its origins. WEBSITE/LINKS: https://lamarzulli.net/ https://www.youtube.com/@TheLamarzulli BOOKS: Rungs of Disclosure: Revised and Expanded On the Trail of the Nephilim The Luciferian Endgame Politics, Prophecy & The Supernatural FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! ETHOS – Life Insurance for Any Budget The #1 no-medical-exam, instant life insurance provider. Get Covered in 10 Minutes. Up to $3 Million in Coverage. Life Insurance Made Easy. Application Times May Vary. https://www.ethos.com HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/
About this episode: For the first time ever, mRNA flu shots are available this respiratory virus season for adults age 50 and older, offering an opportunity to create vaccines better tailored to certain strains of the virus. Moderna's mFLUSIVA was approved by the FDA this summer and is available in some pharmacies. In this episode: Vaccine expert Anna Durbin explains how the vaccine works, discusses the current data on its safety and efficacy, and reflects on the quest for a universal flu vaccine. Guest: Dr. Anna Durbin is a professor of International Health and the director of the Johns Hopkins Center for Immunization Research. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: New mRNA Flu Vaccine Makes This Flu Season 'One to Watch'—Johns Hopkins Bloomberg School of Public Health August 5, 2026 Clinical Review - MFLUSIVA—FDA How Influenza (Flu) Vaccines Are Made—CDC How Flu Viruses Can Change: "Drift" and "Shift"—CDC The Long History of mRNA Vaccines—Johns Hopkins Bloomberg School of Public Health A Guide to Fall Vaccines for People Who Are Immunocompromised and Those Who Care For Them—Public Health On Call (September 2026) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. You can also email PublicHealthQuestion@jhu.edu to request a transcript. AI disclosure (as of September 2026): The conversations you hear on the podcast are happening between real humans, and real humans are developing and researching episodes behind the scenes. In addition to real human audio engineers, Public Health On Call uses AI production tools to assist with the removal of filler words and improve audio quality. If you have any questions about our use of AI, please reach out to PublicHealthQuestion@jhu.edu. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @PublicHealthPod on Bluesky @PublicHealthPod on Instagram @JohnsHopkinsSPH on Facebook @PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
How safe is our food supply?? Dr. Jess Steier kicks off a new season of Unbiased Science with a fresh format! Each episode tackles one concern or question that's gone viral online. It can be hard to know what to trust, so each episode this season tackles one question head-on. Between this summer's Cyclospora outbreak linked to lettuce and the constant stream of food recalls in our feeds, this week we're joined by Dr. Michael Osterholm, director of CIDRAP at the University of Minnesota, along with other experts, to dig into how our food is kept safe and when we should worry. You can also watch the convo on YouTube: https://youtu.be/QGiFDLSEAbM (00:00) Season and Episode Intro (10:11) Introducing Dr. Mike Osterholm (11:27) Early Days of the Summer Cyclospora Outbreak (18:15) What Does the Expert Say to People Who Are Worried About Outbreaks? (20:35) Is There An Increase In Food Safety Issues? (25:57) Former FDA Food Scientist Shares Her Perspective (28:32) Could We Find The Cause Right Now? (30:45) Is There Anything The Expert Avoids? (33:44) Immunotoxicologist Food Safety Expert Shares His Perspective (36:15) What Can We Do To Make The Food Supply Safer? (40:20) Final Thoughts https://www.theatlantic.com/ideas/2026/09/food-safety-crisis-trump-cyclospora/688495/ https://www.theatlantic.com/health/2026/09/foodborne-illness-recall-cyclospora-summer/688497/ https://time.com/article/2026/08/26/e-coli-salmonella-cyclospora-is-the-u-s-seeing-a-surge-in-foodborne-illnesses-/ https://jamanetwork.com/journals/jama/fullarticle/2852106 https://www.nejm.org/doi/full/10.1056/NEJM199605163342001 https://www.nejm.org/doi/abs/10.1056/NEJM199705293362210 https://drjessicaknurick.substack.com/p/why-foodborne-illness-is-surging https://yourlocalepidemiologist.substack.com/p/foodborne-illness-increase-common https://www.wral.com/news/state/diarrhea-parasites-glass-us-food-less-safe-august-24/ https://downloads.regulations.gov/FDA-2013-N-0013-0178/content.pdf https://www.nejm.org/doi/abs/10.1056/NEJM199705293362210 https://www.cidrap.umn.edu/ https://sprout.link/cidrap_ https://www.instagram.com/cidrap_?stkn=czA0d3cxczB2emdy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
On this episode of Vitality Radio, Jared closes out the Intelligence of Symptoms series by looking at fatigue, water retention, depression, and anxiety through a different lens. Could these symptoms be signals that the body is asking for something rather than problems that simply need to be suppressed? Jared explores the roles of sleep, chronic stress, screen time, circadian rhythm, electrolytes, digestion, nutrition, and the gut-brain connection. He also examines the long-standing chemical imbalance theory of depression, discusses MTHFR and folic acid metabolism, and shares Jen's personal experience with mental health and nutrition. The goal is not to ignore serious symptoms, but to ask better questions about what may be driving them and how supporting the body's normal function can help restore resilience.Additional Information:***Watch for all 4 parts of this series on Symptoms!671: Are We Medicalizing the Human Experience? with Dr. Roger McFillinVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.comhttps://drtalks.com/channel-growth
Send Zorba a message!The FDA has approved a new over-the-counter pain medication that combines acetaminophen with naproxen. Zorba weighs in on why now, and what this could be useful for. He helps out a caller with questions about vitamins to help with memory. He fields emails about GERD and prostate medications, we hear a Pavlovian Mom Joke, and Zorba reminisces about a horrible first date he had when he was 16 at a restaurant in Chicago.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 cont either CZP or ADA throughout PREG. Rates of miscarriage, LBW, congenital anomalies, comparable w/ https://t.co/H5GLrvxwPv SELECT-PsA 2 subanalysis of 195 active PsA not responding to TNFi shows switching to upadacitinib 15 (vs PBO) was superior @wk 24 - ACR20 (58% vs 22%), ACR50 (38% vs 9.5%), ACR70 (22% vs 0%), MDA (24% vs 3%) & maintained thru wk 152. Switching MOAs makes sense! https://t.co/YEkZuQ95Mu Do biologic Rx lower risk of PsA? Metanalysis (15 studies, 124,138 psoriasis pts, 778K PYrs F/U), showed Biologic use assoc w/ lower risk of PsA (HR 0.54); best for IL-17i (0.65) & IL-12/23 or IL-23i (0.46) vs TNFi. IL-23i superior to IL-17i (HR 0.67) https://buff.ly/N4froBW OL study of tofacitinib in 20 juvenile DM pts w/ calcinosis cutis (11 boys; age 10.4 yrs; CC x 31 mos). Calcinosis assessed by CT scan showed decr Agatston score from 6,349 to 4,007. No SAE. https://t.co/UDLLwce3mp Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & LDL https://buff.ly/VQNvSI9 TriNetX retrospective EHR study showed VTE in #RA not incr by taking JAKi. Pts undergoing THA/TKA Rx w/ JAKi (n 284) vs TNFi (n 288). VTE- 17 JAKi (6%) vs 11 TNFi (3.8%)- nonsignif incr (RR 1.57) https://t.co/OM5ipieQtr In 2022, Overweight & obesity affect 65.8% of Swiss PsA pts (vs gen pop.= 43%) and has increased since 2007. Obesity was assoc w/ elevated CRP (56% vs 37%), Inc Pt global assess (3.2 vs 2.8), & MD global (2.5 vs 2.1) & lower EQ-5D-3L(0.7 vs 0.8). https://t.co/xPoy4dgvlD Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved 1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ Estimated 7 million Americans (~1/3 US GLP1 Rxs) get GLP-1 drugs from online compounding source- but these are not FDA approved. They maybe cheaper, but dosing/quality is suspect. FDA needs to close the 503B loophole to outlaw these copycat Rxs https://buff.ly/xezDWaJ Data presented at 2027 ASMBS meeting showed betw 2020-2024, wt loss surgeries dropped 23%, from 230,000 in 2022 to 177,000 in 2024. Less than 1% of eligible pts are now having weight-loss surgery https://t.co/UnYIIBDdnz Together PsA 52 wk data (n 271): ACR50 plus 10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus 10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1 FDA Approves Brepocitinib to Treat Dermatomyositis Necrotizing arteritis is rare w/ IgA Vasculitis (IgAV). Review compared 30 IgAV-NA to 257 adult IgAV & 196 PAN pts. Overall IgAV-NA is a severe IgAV phenotype with life-threatening complications & should prompt vascular imaging and intensified immunosuppression. IgAV-NA had more more GI bleeds, perforation, surgical abdomen, neuropathy, pancreatitis, livedo, more multi-organ involvement and mortality https://t.co/XdPbGX770D
Jack Smith's Senate testimony on Tuesday included a mix-up by Republican Sen. Eric Schmitt over an Iowa Hawkeyes game, which Schmitt believed was an Atlanta Hawks game. Ed O'Keefe has more.Lindsay Clancy was back in court on Tuesday, where her lawyer, Kevin Reddington, said the "entire case is based on speculation." Shanelle Kaul and Caroline Polisi have more.Retatrutide is the latest experimental weight-loss drug with promising clinical trial results, but it's not yet approved by the FDA. Dr. Céline Gounder has the latest.Chicago's first AI-driven school, called "Alpha," opened this month. Ash-har Quraishi gets an inside look.Dr. Tania Elliott, a dual board-certified internist and immunologist, joins "CBS Mornings" to offer tips on dealing with fall allergies.Lady A band member Charles Kelley shared a rare blood cancer diagnosis on Tuesday, saying he feels hopeful about the outcome. Adriana Diaz has more.Elias Weiss Friedman, known as the Dogist on social media, joins "CBS Mornings" to announce the top three finalists for People's "World's Cutest Rescue Dog" contest. Winners will be announced on Oct. 19.In a new series called "Between Us," "Big Brother" host Julie Chen Moonves sits down with "The Amazing Race" host Phil Keoghan to discuss their careers on some of television's longest-running reality shows.
From Classroom Idea to FDA-Approved Medical Device What happens when a student sees a life-threatening problem and refuses to accept that “this is just the way it's done”? On this episode of the Cedarville Stories podcast, host Mark Weinstein talks with Dr. Tim Norman, Distinguished Professor of Mechanical and Biomedical Engineering, and Dr. Lauren Edmondson, a 2019 Cedarville graduate and physician, about an innovative medical device that began as a student idea in 2018 and has now received FDA approval. While taking an EMT course at Cedarville, Lauren encountered a story about a traumatic carotid artery injury in which a medic had to hold pressure on a patient's neck throughout the entire trip to the hospital. The experience sparked a question: Could a device provide the necessary pressure while freeing the medic to care for other patients? That question became the foundation for the Arterial Restriction Clamp (ARC). Lauren brought the idea to Dr. Norman, who assembled a senior design team of engineering students to develop a solution. The result is a lightweight, multifunctional device designed to address difficult bleeding situations while allowing medical professionals to continue providing care. In this episode, hear about an allied health student and engineering professor's collaboration across disciplines, the years of testing and research required to pursue FDA approval, the challenges of securing a patent and funding development, and the team's vision for bringing the device to military medics and other first responders. More than a medical innovation, the ARC represents the power of interdisciplinary collaboration, student initiative, and problem-solving with a purpose. What began as a Cedarville senior design project has grown into an effort with the potential to help save lives and bring patients home to their families. Listen to this inspiring story of faith, innovation, perseverance, and a student idea that became a life-saving technology. https://www.youtube.com/watch?v=T11y8zUsv4Ihttps://share.transistor.fm/s/4d10afc9
Send Zorba a message!The FDA has approved a new over-the-counter pain medication that combines acetaminophen with naproxen. Zorba weighs in on why now, and what this could be useful for. He helps out a caller with questions about vitamins to help with memory. He fields emails about GERD and prostate medications, we hear a Pavlovian Mom Joke, and Zorba reminisces about a horrible first date he had when he was 16 at a restaurant in Chicago.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!
Before her diagnosis, Melinda Nelson was a plant-based health coach, avid organic juicer, triathlete, and yogi. At 32, she was diagnosed with adrenocortical carcinoma, a rare, one-in-a-million cancer with only one FDA-approved treatment. She found motivation and inspiration in the documentary Heal, which she played on repeat as she fell asleep. After surgery to remove a cortisol-secreting, 24-centimeter adrenal tumor, she started treatment but experienced recurrence in her spine, hips, shoulder, lungs, and liver, leading her to pursue multiple treatments and procedures with a dedicated team of specialists. Her tumors have remained stable and inactive since November 2022, and she continues to support her well-being through complementary practices such as acupuncture, hypnotherapy, and sound baths. In 2024, Melinda became a founding member and vice president of Adrenal Cure Collective, a nonprofit dedicated to advancing adrenal cancer research, and she now co-hosts Talk Cancer to Me, a podcast exploring the realities of life with cancer beyond oncology appointments. adrenalcurecollective.org Tiktok and Instagram: @Melindacnelson Talk Cancer to Me Podcast Radical Remission Docuseries Trailer to Heal Documentary _________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Join our mailing list and you'll receive our free eBook, Kickstart Your Healing: 20 Radical Remission Tips, as a special thank you for joining. Subscribe Here To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. Follow us on Social Media: Facebook Instagram YouTube ______ Our Sponsors: Immunocine Cancer Center is focused on advancing personalized cancer immunotherapy by harnessing the power of the immune system. Their work centers on the Immunocine Dendritic Cell Treatment (IDCT) — a first-in-class therapy designed to train the immune system to recognize and respond to a patient's specific cancer. The process begins by collecting information from the patient's tumor and using it to program specialized immune cells called dendritic cells, which help activate targeted immune responses. A key differentiator in Immunocine's approach is something called double loading — cancer information is delivered to the dendritic cell both inside the cell and on its surface, giving the immune system a more complete blueprint of the cancer it needs to recognize and attack. And while this approach is unique to Immunocine and unique to use therapeutically, it is NOT unique to biology - since this is how the immune system was always meant to work! Immunocine treats patients from around the world at its clinic in Cancun, Mexico, combining advanced immune science with personalized care. As always, patients should first explore whether they may be eligible for a clinical trial in the United States. To learn more, visit Immunocine.com. Website Links https://immunocine.com/ Social Media Instagram — https://www.instagram.com/immunocine/ YouTube — https://www.youtube.com/@immunocinecancercenter Linkedin — https://www.linkedin.com/company/immunocine/ Facebook — https://www.facebook.com/Immunocine/ ____________________________ Nestled in the pristine, natural beauty of British Columbia, The Healing Oasis stands as Canada's first-of-its-kind cancer wellness retreat, where hope reignites and the body is empowered to heal. Here, our renowned naturopathic cancer expert, Dr. Sean Ceaser, designs a fully personalized protocol of advanced, non-toxic therapies—including high-dose IVs like mistletoe and vitamin C, cutting-edge hyperthermia, PEMF, oxygen therapy, red light, and more. Savor daily organic, cancer-fighting meals, rest deeply in serene cabins, immerse in restorative activities like forest walks and yoga, drink mineral-rich living water, and receive emotional support in a peaceful sanctuary that combines world-class care with profound nature immersion to reduce side effects, boost vitality, and spark radical healing. Your journey to feeling alive again begins today at thehealingoasis.ca. Learn More about The Healing Oasis: Website Testimonials Video Overview
Something on your mind? Erica & Jules would love to hear from you! In this episode, Jules and Erica talk about recent gluten-free recalls, the current state of the FDA and federal recalls vs. brand-led recalls, and why gluten-free certification matters. Jules also shares about her recent trip to Ireland, where she was met with enough gluten-free fish & chips for a small Irish seaside village. For our VIP listeners, did you catch the bonus musical number at the end of the show? RESOURCESgfJules Gluten-Free Dublin IrelandFDA Recall - Eat GANGSTER + AIPContact/Follow Jules & EricaFind us on IG @CeliacandTheBeast & @gfJulesFollow us on FB @gfJules & @CeliacandTheBeastThreads @CeliacandTheBeast & @gfJulesEmail us at support@gfJules.comFind more articles, recipes & info at gfJules.com & celiacandthebeast.comThanks for listening! Be sure to subscribe!**some links may be affiliate links; purchasing through these links will not cost you more, but will help to fund the podcast you ❤️
In today's episode, we spoke with Kim A. Reiss Binder, MD, about the August 2026 FDA approval of daraxonrasib (Rasonque) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent systemic therapy. Dr Reiss Binder is the assistant program director of the Hematology/Oncology Fellowship Program and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania in Philadelphia.In our exclusive interview, Dr Binder discussed the significance of this approval, key efficacy data from the pivotal phase 3 RASolute 302 trial (NCT06625320), and the importance of continuing to build off of treatment advances to drive clinical research and improve patient outcomes in this field.
In today's episode, we spoke with Alissa Cooper, MD, and Noura Choudhury, MD. Dr Cooper is a physician at Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School in Boston, Massachusetts, and Dr Choudhury is an assistant professor of medicine at the University of Chicago in Illinois.In our exclusive interview, Drs Cooper and Choudhury discussed the evolving role of DLL3-targeting T-cell engagers in small cell lung cancer (SCLC), with a focus on tarlatamab-dlle (Imdelltra) and how emerging trial data may reshape the current treatment paradigm across lines of therapy.The discussion opened with the ongoing phase 3 DeLLphi-305 trial (NCT06211036), which is evaluating tarlatamab plus a PD-L1 inhibitor as first-line maintenance therapy following chemoimmunotherapy. Dr Choudhury noted that a positive readout from DeLLphi-305 could significantly diminish the future role of lurbinectedin (Zepzelca) in the maintenance setting, but emphasized that any adoption of tarlatamab as a standard maintenance strategy would require a clear and meaningful overall survival benefit, as well as a favorable toxicity profile compared with existing options. Dr Cooper added that a key outstanding question is whether tarlatamab will carry a different toxicity profile in the maintenance setting compared with the induction and maintenance setting, where higher disease burden may increase the risk of cytokine release syndrome (CRS).The conversation also addressed the investigational agent obrixtamig, another DLL3 x CD3 bispecific T-cell engager in early-phase development, and how clinicians should think about differentiating these agents as the field matures. Both physicians noted that cross-trial comparisons remain premature given differences in study populations and development stage, and expressed that DLL3 testing requirements for investigational agents are unlikely to carry over into a future approved label, consistent with tarlatamab's current FDA indication.On the question of DLL3 immunohistochemistry testing in routine practice, both physicians acknowledged a shifting perspective. While DLL3 is highly expressed in approximately 85% to 90% of SCLC tumors, real-world access to testing varies significantly, and logistical delays may outweigh the benefit of waiting for results before initiating treatment in a disease that can progress rapidly. Dr Choudhury noted that her viewpoint has evolved as emerging data suggest that certain molecular subtypes may derive little benefit from tarlatamab, making more informed patient selection increasingly important. Both agreed that an ideal solution would involve a rapid, commercially integrated assay, but cautioned that liquid biopsy approaches remain hypothesis-generating at this stage.Finally, Drs Cooper and Choudhury reflected on the growing body of real-world experience with tarlatamab since its FDA approval, highlighting ongoing efforts to better characterize who is at highest risk for serious toxicities such as high-grade CRS and immune effector cell–associated neurotoxicity syndrome. Dr Choudhury described a future vision of a risk stratification calculator that could guide decisions about which patients still warrant monitored inpatient administration even if the label is updated to allow outpatient use.
In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving administration strategies for multiple myeloma therapies, primarily focusing on subcutaneous and on-body administration. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.In the first episode of a 3-part series, Drs Faiman and Ailawadhi outlined the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. They also highlighted the significance of the July 2026 FDA approval of satuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications, which includes administration with the CirCLIQ on-body delivery system.
What if caring for your family's health started with asking better questions?As moms, we spend so much of motherhood caring 4 everyone else that it can be easy to put our own health on the back burner. And for anxious moms, the amount of health information out there can feel overwhelming.Today on Faith For Anxious Moms, I'm joined by Dr. Carly Egoavil, a licensed chiropractor & functional medicine practitioner w/ more than 15 years of clinical experience, and Dr. Rachel Marynowski, a licensed naturopathic physician w/ more than 20 years in healthcare.Together, they are Kale Blossom—two moms and physicians who have created an online community and are a huge resource for moms who want to become more informed about their health and the health of their children.In this conversation, we talk about what a functional approach to health means, how it differs from conventional medical care, from immunization schedules to recent study findings on Tylenol, we talk about how moms can become informed advocates for themselves and their families.And because motherhood doesn't leave much time for long conversations, we finish with a rapid-fire round covering everything from organic food, cookware, walking after meals, sauna vs. cold plunge, & where moms can start supporting their health today.Whether you're a SAHM, a working mom, or somewhere in between, caring for yourself is part of caring for the family God has entrusted to you. And just as we turn to faith, Scripture, a Bible verse, or a Bible study when we need wisdom for the challenges of motherhood, we can also give ourselves permission to ask questions and learn about our health. Find Kale Blossom on Instagram at @kaleblossom and explore the resources they recommend for finding practitioners and learning more about functional health.This episode is for educational and informational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment.ENJOY friends and HAPPY WEDNESDAY!Leave a ReviewBecome an InsiderLynn's DevotionalInstagramLYNN's Amazon StorefrontLinktreeMy GUEST: @KaleBlossom on Instagramwww.kaleblossom.comNook, Low Tox Home Scanner App - Kale Blossom********************This Episode Is Sponsored by Lovebug ProbioticsAs moms, we spend so much time caring for our children, our families, and everyone around us that taking care of ourselves can easily fall to the bottom of the list.This episode of Faith for Anxious Moms is brought to you by Lovebug Probiotics, a mom-founded probiotic brand created to make supporting your family's gut health a simple part of everyday wellness.Lovebug's story began with motherhood. During the birth of her son, Hudson, co-founder Ashley Harris received broad-spectrum antibiotics. That experience led Ashley to start learning more about the gut microbiome and ultimately inspired her to create Lovebug — science-backed probiotics made with moms and families in mind.Lovebug offers thoughtfully formulated probiotics for different ages and stages, with options for babies, toddlers, kids, women, and adults. Their probiotics are designed to support digestive and immune health as one simple addition to your family's everyday wellness routine.*Lynn also had the opportunity to personally try LOVEBUG Immune Support Probiotic and especially liked the increase in regularity without the upset stomach & the simple once a day dose, and ease of adding to her supplement regimen.Because caring well for the people we love includes remembering to care for ourselves, too.Ready to find the right Lovebug for you and your family?Shop Lovebug Probiotics Use code FAITHFORMOMS20 for 20% OFF YOUR FIRST PURCHASE.These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Two of the most widely used chemotherapy drugs in the world, 5-FU and capecitabine, have been in use since the 1950s. A small share of patients carry variants in a gene called DPYD that slow their ability to break these drugs down, which means a standard dose behaves like an overdose in their body.A single genetic test can identify those patients before the first treatment. Europe recommended universal screening in 2020. The FDA updated the labels for both drugs in 2025, after years of pressure from families who had lost someone.In this episode of Patient From Hell, host Samira Daswani speaks with Dr. Gabe Brooks, a medical oncologist at the Dartmouth Cancer Center, about what DPD deficiency is, what severe toxicity actually looks like, how and when to get screened, what the test costs, and the exact question to ask before starting either drug.Guest: Gabriel Brooks, MD, MPH, is a medical oncologist and Associate Professor of Medicine at the Dartmouth Cancer Center and the Geisel School of Medicine. He co-directs the Cancer Population Sciences Research Program and specializes in gastrointestinal cancers, including colorectal cancer.Chapters00:00 Introduction00:27 What DPYD is and why it matters02:50 When toxicity turns fatal04:21 5-FU vs. capecitabine06:16 Which cancers use these drugs06:53 What the FDA changed08:26 Why the U.S. took five years longer than Europe11:27 Warning signs and time to onset15:28 How and when to get screened17:39 Germline DNA vs. tumor genomic testing20:16 The patient advocacy behind the change24:44 What to ask your oncologist26:43 What the test costs28:18 Closing thoughtsResources: Advocates for Universal DPD/DPYD Testing — test4dpd.org
Your TBR (AKA “to be read”) list may be pretty long if you're a student, if you're trying to keep up with the trends on Book Tok, or if you've just made a trip to your favorite local bookstore. Our two guests on this episode of the SNMMI podcasts also have extensive reading lists, but they're not New York Times best sellers — they're images of the human brain. Jake Dubroff and Derek Johnson both work in clinics that conduct amyloid and tau PET imaging at high volumes. The scans they're reading give providers insight into what's going on in the human brain, particularly when it comes to diagnosing Alzheimer's and other neurodegenerative diseases. But the use of the scans isn't nearly as widespread as it could be, mainly due to implementation barriers. Even so, things seem to be changing, especially with the FDA's approval of FET that was only recently announced. To learn more about navigating the work that goes into reading scans, how clinics handle high volumes of patients, and the future role of nuclear medicine in brain imaging, tune into the discussion. Now streaming wherever you listen to podcasts!This episode of the Podcast is sponsored by GE HealthCare.Vizamyl Important Safety InformationPRODUCT INDICATIONS AND USEVIZAMYL™(flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:Evaluation of Alzheimer's disease(AD) and other causes of cognitive declineSelection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.CONTRAINDICATIONSVIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.ADVERSE REACTIONSThe most commonly reported adverse reactions in clinical trials were flushing(2%), increased blood pressure(2%), headache nausea and dizziness(1%).Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi Want more SNMMI content? Follow us on:YouTube | Instagram | LinkedIn | Twitter/XWant more SNMMI content? Follow us on:YouTube | Instagram | LinkedIn | Twitter/X
Alex Hearding is the founder and president of Red Wolf Risk, a risk management and compliance firm serving the cannabis industry. With more than 17 years of experience in cannabis operations and risk management, Alex brings a unique perspective shaped by firsthand experience as an operator and years advising businesses on safety, quality, insurance, and regulatory compliance. Today, his work focuses on helping cannabis companies build stronger, more resilient operations and prepare for an increasingly federalized regulatory environment through practical risk management, quality systems, and GMP and FDA readiness.
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this special episode of Mind Moments, released in recognition of Limb-Girdle Muscular Dystrophy (LGMD) Awareness Day on September 30, Katherine Mathews, MD, professor of pediatrics and neurology at the University of Iowa Carver College of Medicine, joins the podcast to discuss the evolving treatment landscape for LGMD and the potential significance of BBP-418, an investigational oral therapy for LGMD2I/R9.With an FDA decision expected by November 27, 2026, BBP-418 could become the first approved therapy for LGMD2I/R9 and potentially the first treatment approved for any form of LGMD. Mathews breaks down the therapy's FKRP-targeted mechanism, findings from the phase 3 FORTIFY study, and the challenges of conducting clinical trials across genetically diverse and slowly progressive forms of LGMD. She also discusses what a first approval could mean for the broader LGMD community, considerations for bringing patients back into specialty care, and research priorities that could accelerate development of future therapies.Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.Episode Breakdown: 1:15 – BBP-418's mechanism and therapeutic rationale for FKRP-related LGMD2I/R9 4:00 – FORTIFY findings supporting BBP-418's potential effects on muscle and pulmonary function 7:50 – Why genetic heterogeneity and slow progression complicate LGMD clinical trials 10:10 – Neurology News Minute 12:45– What a first FDA-approved LGMD therapy could mean for patients and clinicians 15:40 – Research priorities for accelerating clinical trials and developing future LGMD therapies The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: CHMP Recommends EU Approval for Ocrelizumab in Pediatric Relapsing MS SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease FDA Approves Tavapadon for the Treatment of Parkinson Disease Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
In this episode of Medical Spa Insider, Alex Thiersch is joined by Patrick Urban, President of Merz Aesthetics North America, and Cheryl Haseeb, DNP, FNP-BC, founder of Pura Medical Aesthetics and the Aesthetic National Institute. They delve into the major shifts transforming the aesthetic medicine landscape, starting with Merz's recent FDA approvals for Belotero Volume and Belotero Intense, and what these additions mean for addressing consumer "filler fatigue" with natural-looking, tissue-integrated results. Discussion points include: 02:08 FDA Approval of Belotero for Lips and Cheeks 03:53 The Shift Towards Natural Results 06:49 Regenerative Aesthetics and Industry Evolution 11:01 Patient Expectations and Education 13:47 The Role of Proper Training and Technique 17:11 Industry Collaboration and Standards 23:49 The Importance of Evidence-Based Practice 28:12 Younger Patients and Preventative Care
In this last episode from ASCRS 2026, Jim Mazzo and John A. Hovanesian, MD, FACS, sit down with Perry J. Sternberg of Sydnexis, Nancy Beesley, and Jean-Pierre Hubschman, MD, of Horizon Surgical Systems, to discuss myopia in children, cataract surgery assisted by AI and robotics, and more. · Welcome Perry J. Sternberg and Nancy Beesley. 0:44 · How and why is SYD-101 different from atropine? 3:20 · What happened with the FDA approval? 8:24 · Tell us about the study. 10:57 · Welcome Jean-Pierre Hubschman, MD. 20:32 · Transitioning from retina to cataracts. 21:02 · How do you address concerns about AI replacing surgeons? 24:19 · Transitioning from physician to CEO. 28:46 We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John A. Hovanesian, MD, FACS, @DrHovanesian on Instagram and X and John Hovanesian on LinkedIn.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative developments across the pharmaceutical and biotech sectors, highlighting strategic investments, innovative therapies, and regulatory milestones. AstraZeneca's recent $2 billion investment in Summit Therapeutics is a testament to the industry's focus on cutting-edge oncology solutions. This substantial funding aims to advance the development of ivonescimab, a PD-1xVEGF bispecific antibody, in conjunction with antibody-drug conjugates. This strategic move underscores the potential of combining different therapeutic modalities to target complex cancer pathways, particularly in gastrointestinal malignancies. By leveraging dual-targeting capabilities, these therapies promise enhanced efficacy, marking a significant step forward in cancer treatment paradigms. Meanwhile, Novo Nordisk is making strides in metabolic disease management through its partnership with Hengrui Pharma. This collaboration to develop a weekly oral GLP-1R/GIPR dual agonist for obesity underscores the growing emphasis on innovative metabolic therapies. The upfront payment of $300 million, with additional milestone payments potentially reaching $2.6 billion, reflects the high stakes involved in addressing obesity—a global health challenge. This approach could revolutionize current treatment standards by improving patient compliance and outcomes through targeted small molecule interventions. On the manufacturing front, Genentech's $750 million expansion of its Hillsboro facility highlights the increasing demand for biopharmaceuticals. This investment is poised to double the facility's size by 2031, supporting new drug approvals in oncology, neurology, and immunology. Enhanced production capacity is crucial for meeting the intricate requirements of biologics and personalized medicine, ensuring that breakthrough treatments reach patients more effectively. In the realm of antibody research, Ginkgo Bioworks, AbbVie, and Takeda have joined forces to form the Antibody Developability Consortium. By creating a standardized dataset for antibody development using artificial intelligence and machine learning, this initiative aims to streamline the discovery and manufacturability of therapeutic antibodies. The collaboration seeks to overcome existing challenges in antibody drug development, potentially expediting time-to-market for new therapies. In neurology, AC Immune's Phase 2 trial of ACI-7104 has shown promising results in early-stage Parkinson's disease by meeting all primary endpoints and demonstrating complete immunogenicity. This active immunotherapy targeting alpha-synuclein presents hope for modifying disease progression rather than merely alleviating symptoms. Such advancements highlight the potential of vaccination strategies in addressing neurodegenerative diseases. Roche is also embracing innovation by planning autonomous AI labs for drug R&D. These labs are expected to accelerate clinical candidate development significantly, reducing costs while improving success rates in bringing new drugs to market. This initiative exemplifies how AI-driven drug discovery is reshaping research methodologies. Despite these advancements, challenges persist within the industry. UniQure's gene therapy for Huntington's disease showed diminished effectiveness over four years in Phase 1/2 trials, illustrating the complexities inherent in developing neurological disorder treatments. Additionally, BioNTech's closure of three sites in Germany resulting in substantial job cuts highlights broader economic pressures despite its success with mRNA vaccines. Regulatory developments are crucial as well. The FDA's approval of Roche's Gazyva for idiopathic nephrotic syndrome marks a pivotal advancement as it becomes the first treatment option for this condition in 70 years. This approval not only provides hope for patients but also sets a precedent for future research into autoimmune diseases. In contrast to these successes, Roche decided to discontinue its muscle-sparing obesity antibody following disappointing phase 2 results. Such outcomes emphasize the importance of interim analyses and adaptive strategies in drug development. Overall, these updates underscore a dynamic period characterized by strategic investments, technological innovation, and collaborative efforts aimed at addressing some of healthcare's most pressing challenges. The integration of cutting-edge technologies such as AI and novel therapeutic modalities continues to drive progress towards more effective and personalized patient care solutions. As we wrap up today's episode of Pharma Daily, it's clear that while opportunities abound within the industry through scientific breakthroughs and strategic collaborations, challenges remain that require careful navigation. Companies that balance innovation with rigorous clinical evaluation will be at the forefront of delivering transformative healthcare solutions globally. Thank you for tuning into Pharma Daily; stay informed with us as we continue to track these evolving trends shaping the future of pharmaceuticals and biotech.Support the show
Shaun Bagai is the CEO of RenovoRx, the company behind the RenovoCath- an FDA-cleared device that uses Trans Arterial Micro Perfusion (TAMP) to deliver high concentrations of chemotherapy directly to tumors that are poorly connected to the systemic circulation, dramatically reducing side effects and improving survival in locally advanced pancreatic cancer. In this episode, Shaun walks us through how he discovered MedTech almost by accident, why he walked away from medical school after getting in, and the leadership philosophy (built on humility, data, and "beautiful friction") that has sustained him through 11+ years of building one of the most innovative cancer therapy companies in the industry. Whether you're a founder navigating a long clinical development road, a commercial leader trying to move physician behavior, or someone who just needs a reminder of why they got into this industry- Shaun's final piece of advice will stay with you: "Focus on that one patient you saw an impact on. Because that's the heart of everyone listening to this podcast."
Tillman Holloway and Andrew Parish are the co-founders of Arch Public. In this conversation, we break down how AI agents and bitcoin are converging, why bitcoin is the best collateral in the world, and what 24/7 markets will mean for investors. We also discuss bitcoin ETF flows, Wall Street's growing role in bitcoin, and why AI trading tools still need a human in control.=======================Arch Public is an agentic trading platform that automates investment strategies across Stocks, Commodities, ETFs and Crypto. Whether you're rotating into AI & Gold, allocating to the S&P 500, or accumulating Bitcoin, Arch Public executes your plan 24/7 without ever taking custody of your assets or funds. Sign up today at https://www.archpublic.com, and start your FREE automated trading strategy! =======================Lava is a global platform for bitcoin financial services. Spend with Lava Card and earn up to 5% back in bitcoin with every purchase— all with no annual fee, no FX fees, and zero spread. Plus you can borrow against your bitcoin at the lowest rates, earn yield on cash, and move fiat or stablecoins globally. Get started at https://www.lava.xyz/POMP=======================GalaxyOne is a financial technology platform built for people who want their cash working harder. Open an account with promo code POMP and deposit $10,000 to earn a $1,000 bonus. See site for promotion details → https://www.galaxy.app/pomp1000 Galaxy Premium Yield is an investment note issued by Galaxy Digital LP and guaranteed by Galaxy Digital Holdings LP. It is not a bank deposit, is unsecured, and is not FDIC or SIPC insured. U.S. accredited investors only. Cash deposits held at Cross River Bank, Member FDIC. Securities products are not FDIC insured, not bank guaranteed, and may lose value. GalaxyOne Crypto is not FDIC or SIPC insured. Terms apply.=======================This episode is brought to you by Investor Health — clinician-prescribed protocols for weight, metabolism, energy, and longevity, delivered to your door in 48–72 hours. No office visits, no referrals. Plans start at $149/mo. Learn more at http://www.InvestorHealth.com/pomp. Investor Health is a telehealth platform, not a medical provider. Compounded medications are not FDA-approved. Individual results may vary and treatment requires evaluation by a licensed provider.=======================0:00 - Intro1:10 - AI agents, bitcoin & crypto as collateral4:18 - 24/7 markets are coming6:40 - Crypto tokens vs AI tokens12:20 - Trust & security with AI agents16:55 - Can AI trade for you 24/7?25:42 - Why people name their AI agents32:53 - Why bitcoin ignores macro headwinds36:16 - Bitcoin ETF flows & retail demand40:01 - Bitcoin price outlook & dip buying43:27 - Elon, X Money & the tech titans45:20 - Future of AI tools & Arch Public
Following the death of 27-year-old Presley Gerber inside a Santa Monica sober living facility, board-certified psychiatrist and former FDA Medical Officer Dr. Josef Witt-Doerring of TaperClinic joins Dr. Drew to examine the fatal risks of overmedicating with psychiatric drugs. Dr. Witt-Doerring analyzes Gerber's disclosures of fluctuating benzodiazepine doses without daily medical oversight, the physiological hazards of unmonitored psychiatric medication tapers, and the emerging panic over gas station kratom. Dr. Mary Talley Bowden breaks down the brewing revolt within the MAHA movement, as health freedom leaders issue an ultimatum to Pres. Donald Trump and RFK Jr. demanding the removal of the mRNA vaccine platform. California Department of Public Health whistleblower Ronald Owens Jr., author of “Muzzled Truth,” exposes how state officials suppressed early COVID-19 treatment warnings from 40 million residents and examines former HHS Secretary Xavier Becerra's controversial public remarks on vaccine mortality. Dr. Mary Talley Bowden completed her residency at Stanford University and is board-certified in both Otolaryngology and Sleep Medicine. She is the author of “Dangerous Misinformation: The Virus, the Treatments, and the Lies” available at https://amzn.to/4rF16CW. Follow at https://breathemd.org Ronald F. Owens, Jr. worked at the California Department of Public Health (CDPH) as an Information Officer 2 during COVID, where he says he learned that then-HHS Secretary Xavier Becerra said COVID-19 vaccines were “killing people.” He is the author of “Muzzled Truth: How The California Dept. of Public Health Rejected COVID-19 Treatment and Vaccine Health Risks Warnings.” Find more at https://muzzledtruth.com Dr. Josef Witt-Doerring is a board-certified psychiatrist and former FDA Medical Officer who is Medical Director of TaperClinic, one of the only practices focused exclusively on helping patients safely de-prescribe from psychiatric medications. He previously worked at Janssen Pharmaceuticals and the FDA's Division of Psychiatry, and hosts the podcast Side Effects with Dr. Josef. Follow at https://taperclinic.com 「 SUPPORT OUR SPONSORS 」 • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - https://kalebnation.com • Susan Pinsky - https://x.com/firstladyoflove Content Producer • Emily Barsh - https://x.com/emilytvproducer Learn more about your ad choices. Visit megaphone.fm/adchoices
Mold exposure symptoms get blamed on flu season every September: headaches, cough, sinus congestion, throat-clearing, fatigue, even nosebleeds. Liz and Becca break down the HHS mold roundtable, the classroom where teachers got sick every year until black mold turned up, the FDA's public workshop on testosterone for women (and the dosing catch), and why Texas banned lab-grown meat. If your family is fine all summer and sick all school year, start here.***→ Get LeelaQ Trusted quantum energy devices used in 86 countries, supporting balance and vitality through a more coherent energetic environment, even in the presence of everyday EMFs***Lets Connect:Connect with Liz: Instagram | YoutubeConnect with Becca: Instagram | YoutubeJoin our private community: FitMom Society***Have questions? Ask HereLooking for answers? Work with us***Want to win FitMom Mystery Box?Leave us Apple Review | Spotify Review***Mentioned in this episode:Leela Quantum TechTry the new Heal360 Advanced Frequency from LeelaQ, it's their most comprehensive wellness frequency system yet, designed to support cognitive wellness, recovery, emotional balance, energetic resilience, and a deeper energetic reset, and a more coherent energetic environment in today's rapidly evolving EMF landscape. It's available in wearable capsules in both brass and titanium, plus convenient frequency cards, making it easy to experience wherever life takes you. Visit leelaq.com and use FitMom code at checkout to get 10% off your next order. That's leelaq.com, code FitMom for 10% off
Hour 3 (09.28) Big-box America knows you’re broke: ALDI is cutting prices on about a third of its stuff — seasonal produce included — through November 3; Walmart’s running Deal Days; Target’s cheap on candy, snacks, and cereal; and Amazon’s discounting fish, meat, and dairy. Then Bellio’s Starbucks-door story and her Andy Garcia story, which somehow end the same way. Disney+ and Hulu jack ad-free to $21.49-plus — stream-flation — while finding the actual game gets harder, and the FDA is close to a blood-cancer test. Replay of the Coliseum ugly: USC linebacker Desman Stephens II’s targeting hit on Oregon QB Dante Moore put him down hard; Moore’s expected to be OK with movement in all extremities, but Stephens and teammates celebrating while he was still on the field was a look nobody needed. Live now: a chase near LAX and Westchester turns into a foot pursuit with CHP on it. Mark’s MCing Kitten Rescue’s Fur Ball at the Skirball this weekend. And Dennis Haskins — Mr. Belding from “Saved by the Bell” — has died at 75. See omnystudio.com/listener for privacy information.
LIVE from ILADS: Tick Boot Camp reconnects with Nicole Bell, CEO of Galaxy Diagnostics, for a focused conversation about one of the biggest challenges in Lyme disease and tick-borne illness: getting an accurate diagnosis. Bell breaks down the differences between antibody testing, antigen testing, and PCR-based direct detection while explaining why stealth pathogens such as Borrelia, Bartonella, and Babesia can be so difficult to find. She also introduces Galaxy's BBB Direct Detect digital PCR testing, discusses emerging findings involving Babesia species, and explains why a negative antibody test doesn't always tell the entire story. For Bell, the mission is deeply personal. Her husband, Russ, initially tested negative for Lyme disease and was later diagnosed with Alzheimer's disease before his family ultimately discovered tick-borne infections were part of his complex illness. That experience helped redirect Bell's engineering and medical technology background toward improving diagnostics for other patients searching for answers. This interview was recorded live at the ILADS conference, so you may hear some of the energy and background activity of the event throughout the conversation. Why Can Lyme Disease Testing Be So Difficult? Bell begins by explaining one of the fundamental problems with diagnosing Lyme disease and other tick-borne infections: many of the pathogens clinicians are searching for can be difficult to detect. Some occur at low levels in the bloodstream. Others may migrate into tissues or circulate intermittently. Historically, much of tick-borne disease testing has therefore relied on indirect detection — looking for the patient's immune response rather than directly detecting the organism. Antibody testing can provide useful information, but Bell explains why interpretation can become complicated. A patient's antibody response can vary depending on factors including: Timing of infection Individual immune response Immune suppression or dysregulation Previous exposure Previous treatment Medications that suppress immune activity Cross-reactivity Whether an infection is current or historical This is why Bell views antibody testing as one tool rather than the entire diagnostic toolbox. Antibody Testing: Detecting the Immune Response Antibody testing is an indirect testing method. Instead of looking for Borrelia itself, for example, the test looks for evidence that the patient's immune system has responded to it. Bell discusses IgM and IgG antibodies and why timing matters. IgM antibodies are generally associated with an earlier immune response, while IgG responses can take longer to develop. In Lyme disease, that delay creates a particular challenge because early diagnosis and treatment can be especially important. Some infected patients may mount a strong measurable antibody response, while others may produce a weaker or delayed response. Bell points to research showing how dramatically immune responses can differ even under controlled experimental conditions. This creates an important distinction: A test of the immune response is not necessarily the same thing as a test for the pathogen itself. When Antibodies Don't Tell the Whole Story Bell uses her husband's experience to illustrate the stakes. Russ had likely been ill for years before his most significant symptoms emerged. By then, Bell says his immune system was dysregulated and his overall antibody levels were low. His Lyme testing was negative, and his worsening cognitive symptoms ultimately led to an Alzheimer's diagnosis. There is also another side to antibody testing. A person may have antibodies because of a previous infection even when the original infection is no longer active. That can make it difficult to determine whether persistent symptoms are associated with an ongoing infection, an undiagnosed coinfection, immune dysregulation, or another process. Bell's point is not that antibody testing has no value. It is that complex tick-borne illness may require more than one diagnostic tool. Antigen Testing: Looking for Evidence of the Pathogen The conversation then moves from indirect testing to direct detection. One method is antigen testing. Rather than measuring the immune system's response, an antigen test searches for a component associated with the pathogen itself. Bell discusses Galaxy's work with a urine-based Lyme disease antigen approach designed to capture and concentrate a protein shed by Borrelia. Why urine? Bell explains that Lyme-causing Borrelia may not remain abundantly present in the bloodstream. A pathogen-derived protein, however, may be filtered through the kidneys and become detectable in urine. Galaxy continues to work on direct-detection approaches to Lyme disease testing as it pursues broader clinical adoption and regulatory pathways. PCR Testing: Searching for Pathogen DNA Another form of direct detection is PCR testing. PCR looks for genetic material from the pathogen rather than relying on the patient's antibody response. Galaxy uses PCR-based approaches for pathogens including: Borrelia Bartonella Babesia But direct detection presents its own challenge. These organisms may occur at extremely low levels in a sample. A patient can be infected while very little pathogen DNA happens to be circulating in the particular blood sample collected that day. That is where digital PCR, or dPCR, becomes especially interesting. The Three B's: Borrelia, Bartonella & Babesia Bell introduces Galaxy's approach to what Tick Boot Camp often calls the Three B's: Borrelia. Bartonella. Babesia. As patient and clinician awareness of tick-borne illness has evolved, these three pathogens have become increasingly important to the conversation around complex cases. Galaxy's BBB Direct Detect digital PCR testing is designed to directly detect DNA from Borrelia, Bartonella, and Babesia. Unlike an antibody test asking whether the immune system has responded to a pathogen, direct PCR testing asks a different question: Can we find genetic evidence of the organism itself? How Digital PCR Searches for Low-Abundance Pathogens Bell gives a simple analogy for understanding digital PCR. Imagine searching for a needle in a haystack. Traditional PCR is trying to identify a tiny amount of pathogen DNA — the needle — among an enormous amount of human genetic material — the haystack. Digital PCR effectively divides that haystack into thousands of much smaller piles and examines them individually. That partitioning can make it easier to detect extremely small amounts of genetic material. Galaxy also uses a culture-enrichment step for Bartonella. The blood sample is placed in an environment designed to encourage Bartonella growth before PCR analysis, increasing the amount of target material available for detection. Learn more about Galaxy Diagnostics' direct-detection technology and its approaches to Borrelia, Bartonella, and Babesia testing. Why Are We Seeing So Many Coinfections? Tick Boot Camp and Bell also discuss an observation that has become increasingly common in patient interviews: many people with complex chronic tick-borne illness aren't reporting only Lyme disease. Instead, patients frequently describe combinations involving the Three B's and other infections. Why? Bell says several factors may contribute. Diagnostic technology has improved. Clinicians have become more aware of coinfections. Ecological research indicates ticks can carry multiple pathogens. But Bell raises another important possibility: patients carrying multiple pathogens may also be among those who become the sickest and therefore are disproportionately represented within chronic illness communities. That distinction matters. Observing many coinfections among severely ill patients doesn't necessarily mean every tick-borne disease patient has the same microbial picture. Bartonella, the Immune System & the Tipping Point Bell discusses Bartonella as an example of the complexity surrounding infection and illness. Exposure may be more common than many people realize, and Bartonella has multiple potential vectors and reservoirs. Bell describes a hypothesis in which some people may harbor an infection while their immune system keeps it under control. Then another infection, environmental exposure, significant stressor, or other immune-disrupting event may alter that balance. A person who had previously remained relatively healthy may cross what Bell describes as a tipping point and begin experiencing significant illness. This raises questions researchers are still working to answer. Were multiple infections transmitted simultaneously? Did they occur through separate exposures? Was one infection already present before another destabilized the immune system? Bell emphasizes that the answer may differ from patient to patient. Emerging Questions About Babesia Some of the most intriguing discussion in this interview involves Babesia. Bell explains that research associated with the North Carolina State University team has identified Babesia species in complex patients beyond the organisms traditionally emphasized in U.S. human babesiosis. She specifically discusses findings involving Babesia odocoilei and Babesia divergens-like organisms and contrasts those findings with expectations surrounding Babesia microti and Babesia duncani. Bell also discusses the possibility of low-level parasitemia — infections involving pathogen levels that may be much lower than the classic severe presentation clinicians associate with babesiosis. These emerging observations raise important research questions about Babesia species, their prevalence, their role in human disease, and whether existing diagnostic assumptions capture the full picture. Bell is careful in the interview to distinguish between what Galaxy's current assay detects and what researchers may suspect based on sequencing and related scientific work. Nicole Bell's Personal Mission Bell's work in tick-borne disease diagnostics grew out of an experience no family wants to have. Her husband, Russ, developed neurological and psychiatric symptoms, including cognitive problems, anxiety and hallucinations. Despite Bell specifically requesting Lyme disease testing early in his illness, his initial test was negative and his diagnostic journey eventually led to an Alzheimer's disease diagnosis. Bell later documented her family's experience in her memoir, What Lurks in the Woods. Today, she brings her engineering background and personal experience together in an effort to improve the diagnostic tools available to clinicians and patients. From MIT & Duke to Galaxy Diagnostics Nicole Bell is CEO of Galaxy Diagnostics and an engineer with extensive experience in medical devices and diagnostics. She earned bachelor's and master's degrees in Materials Science and Engineering from MIT and a master's degree in Biomedical Engineering from Duke University. Before joining Galaxy, she worked in technology and medical-device development, including leadership roles involving diagnostic platforms and FDA submissions. Bell became CEO of Galaxy Diagnostics in 2024, bringing together her professional background in engineering and diagnostics with the lessons learned through her husband's illness. The State of Lyme Disease Research Bell is also the primary author of The State of Lyme Disease Research in the United States for the Center for Lyme Action. The paper examines gaps in Lyme disease research and outlines recommendations involving fundamental science, diagnostics, prevention, treatment, and research infrastructure. In this interview, Bell references one particularly important issue explored in that work: delays in Lyme disease diagnosis and treatment are associated with a greater risk of patients experiencing persistent symptoms. Better testing isn't simply about producing a more sophisticated laboratory report. It's about helping clinicians get patients appropriate answers earlier. Key Topics in This Episode Lyme disease testing, Lyme diagnostics, Nicole Bell, Galaxy Diagnostics, Borrelia testing, Bartonella testing, Babesia testing, Three B's, BBB Direct Detect, digital PCR, dPCR, PCR testing, antibody testing, antigen testing, direct detection, indirect testing, stealth pathogens, Lyme disease antibodies, coinfections, polymicrobial tick-borne disease, low-abundance infections, Bartonella culture enrichment, Babesia microti, Babesia duncani, Babesia odocoilei, Babesia divergens, chronic Lyme disease, diagnostic delays, and tick-borne disease research. About This LIVE from ILADS Interview This short-form conversation was recorded in person at the 2025 International Lyme and Associated Diseases Society Annual Scientific Conference, From Terrain to Treatment: Advances in Vector-Borne Illness, held October 9–12, 2025, in San Antonio, Texas. Because these interviews were recorded live at the conference, they have a different feel from Tick Boot Camp's traditional long-form virtual and studio conversations — shorter, focused, and surrounded by the activity of one of the world's major gatherings of Lyme and tick-borne disease clinicians, researchers, advocates, and innovators. Explore all Tick Boot Camp LIVE from ILADS interviews. More from Tick Boot Camp Hear more conversations with Lyme disease doctors and healthcare professionals about testing, diagnosis, treatment, and complex tick-borne illness. Explore the Tick Boot Camp Podcast for interviews with patients, doctors, researchers, advocates, and innovators working to improve understanding of Lyme disease and help people move toward recovery.
Episode 16 - Dr. Lawrence Lustig explains Otofarmaní, the newly FDA-approved gene therapy offering a potential cure for a rare genetic form of childhood deafness.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only. The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees. We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.
So why do so many medical device startups fail to account for a danger that could bring their whole business crashing down? In this episode of Predictable B2B Success, Vinay speaks to Christian Espinosa, the founder of Blue Goat Cyber, about the little-known aspects of cybersecurity in the medtech field a risk that is so badly underestimated that even the best industry articles and founder discussion forums fail to touch on it. Nevertheless, Christian Espinosa has built a successful, bootstrapped business by charging as much as $150,000 per engagement to address this oversight, having supported more than 250 FDA submissions in the process. Why is cybersecurity still treated as something added at the end rather than an essential part of device design? What are the consequences when a shortcut costing $5,000 turns out to cost $500,000? How do you achieve steady revenue and provide a written guarantee on your website when prospects only realize they need you after regulators have said "no"? Vinay puts Christian Espinosa on the spot on pricing, positioning, industry reactions, and lessons from a previous exit that went wrong. If you care about security, entrepreneurship, or overcoming market indifference, you won't find this point of view anywhere else. Listen in for valuable insights under pressure, useful takeaways, and a frank look at the challenges facing the overlooked medtech sector behind the scenes. Some topics we explore in this episode include: An invisible threat that few startups discuss: why is cybersecurity omitted from the vast majority of medtech failure post-mortems, and might your industry be ignoring a similar risk?The demand for things that no one is actually buying: how do you promote a solution for CEOs who don't (at this stage) think they need it? Learn about unorthodox methods to build awareness and create urgency.What really occurs when essential compliance work is delayed until the 11th hour? Regulatory surprises that cause product launches to failCan you carry out bold positioning campaigns without losing sight of your company's values?Why will some customers pay 20 times as much in a commodity market, and how can you design your offerings so that competitors can't realistically match them?Security (or indeed any technical service): could the actual value lie in the paperwork that goes uncredited?How failing to address security early can blow up your timeline: a real account of thousands of vulnerabilities discovered right before launch. When is your 'oh no' moment?Should you assess risk based on what matters most to your customers, or are you merely following industry dogma?Can offering your best tools for free generate more leads than lead magnets and email campaigns?What would you do differently if you had trusted the wrong people to be promoted, or if you realized that your highly praised exit had, in fact, not been a success?
Bringing a healthcare innovation to market takes more than a great idea. It takes navigating a complex and constantly changing regulatory landscape.On this episode of the Medical Alley Podcast, we sit down with Mark Gardner, Nate Downing, and Amanda Johnston from Gardner Law to discuss the FDA and CMS issues facing medical technology and healthcare companies.This conversation explores CMS's Rapid program and changes to NTAP, FDA leadership and review priorities, and how AI may shape regulatory submissions. Learn practical perspectives on advertising, compliance, privacy risks and look ahead to emerging technologies such as wearables and brain-computer interfaces. Whether you're building a healthcare company or following the future of medical innovation, this episode offers insight into the challenges and opportunities on the path from idea to patient.Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.
Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals.The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and lingering questions about her independence, new pharma tariff guidance that leaves exemptions unclear, and how reverse mergers paired with nine-figure PIPEs became a viable IPO alternative. Plus, Merck's $400 million upfront bet on a preclinical KRAS G12C molecular glue.View full story: https://www.biocentury.com/article/660935#IgANephropathy #FDA #BiotechIPO #DrugDevelopment #ClinicalTrials0:00 Introduction1:30 Grand Rounds: Europe Recap6:03 IgA Nephropathy Pipeline14:57 Overton Hearing22:19 Commerce's Tariff Guidance24:28 Reverse Mergers' New LookTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
This episode is about psychedelics and grief, and it starts from an unusual place: not death, but everything else grief actually is. Loss of a future you thought you had. Loss of an identity, a marriage, a body that no longer works the way it used to. That's the frame Dr. Sunil Aggarwal and I set for this final Psychedelic Salon of last season, recorded live at Town Hall Seattle.Sunil isn't a hospice tourist to this topic. He's a physician at Seattle's AIMS Institute who has spent years fighting, in federal court, for his own terminally ill patients' right to try psilocybin. He was the first doctor to petition the DEA for Right to Try access on their behalf. We talk about the neurobiology of why a guided psychedelic experience can shift a story you've carried about a loss for years, a bereaved-parent retreat in Jamaica that's now the subject of a real qualitative study, and the distinction Sunil keeps returning to, containment versus integration.Containment is what most of us default to. Put the loss in a box, keep functioning, call it managed. Integration is slower, and it's the only version of the two that actually changes your relationship to what you lost. Not less pain. A different relationship to the pain.We also get into what the research does and doesn't support, from the fast-tracked synthetic psilocybin analogs now moving through the FDA to the early, mostly preclinical evidence on psilocybin and brain injury. And we close on the one resource almost nobody uses: every hospice in the country is legally required to offer 12 months of bereavement support, to anyone in the family, whether or not you were ever a patient there.Subscribe to April Pride on Substack for weekly conversations on psychedelics, nervous system health, and integration.0:00 Welcome, disclaimer, and the topic of this Salon: grief 0:45 Meet Dr. Sunil Aggarwal: hospice, palliative medicine, and medical geography 2:20 The Right to Try fight to get psilocybin to dying patients 5:00 Who controls psilocybin's Schedule I status, and why the FDA's fast-tracked analogs won't change access for most people 6:30 April's own experience with grief, and the parents who come to her after losing a child 8:30 How Sunil recognizes grief in a clinical setting, and what anticipatory grief looks like 11:30 Containment versus integration 12:20 Inside the Jamaica grief retreats for bereaved parents 17:20 The neurobiology of psilocybin, the default mode network, and reframing a loss 19:10 How to integrate a psychedelic experience afterward 22:20 The bereavement benefit almost no one uses 23:40 Key takeaways and what's ahead this seasonDr. Sunil Aggarwal is a physician at Seattle's AIMS Institute, where he leads an integrative oncology and palliative care practice and directs the clinic's psychedelic-assisted work with ketamine and psilocybin. He holds an MD and PhD from the University of Washington School of Medicine, where his doctoral work was in medical geography. Aggarwal was the first physician to petition the DEA for Right to Try access to psilocybin for terminally ill patients, litigation that produced a Ninth Circuit ruling finding the DEA had erred in denying that petition, a first for the agency. His clinical and legal work sits at the center of the current fight over who gets access to psychedelic medicine, and under what conditions, before federal rescheduling catches up.@sunil1007 @aimsinstituteseattle
Psychic medium Sloan Bella returns to Strange Planet for a journey beyond the headlines—into the Charlie Kirk assassination, secrets inside the Royal Family, Bill Gates and global power, UFO disclosure, AI and the chilling possibility of the Antichrist. What does Sloan see coming next—and are we ready for it? GUEST: Sloan Bella is a Hollywood psychic medium, astrologer, author and metaphysical teacher who has spent decades reading the people, patterns and unseen forces behind major cultural events. Known for her provocative predictions and fearless investigations into celebrity, politics, the paranormal and prophecy, Sloan looks beyond the headlines to what she believes is really unfolding. WEBSITE/LINKS: https://sloanbella.com/ https://www.youtube.com/sloanbella FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet SUPPORT OUR SPONSORS!!! ETHOS – Life Insurance for Any Budget The #1 no-medical-exam, instant life insurance provider. Get Covered in 10 Minutes. Up to $3 Million in Coverage. Life Insurance Made Easy. Application Times May Vary. https://www.ethos.com HIMS Weight Loss By HIMS -HIMS now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy® pill and the Wegovy® pen. Ready to reach your goals? Visit hims.com/strangeplanet to get a personalized, affordable plan that gets you. MARS MEN Mars Men helps you reclaim your edge with natural testosterone support for energy, focus, and strength Go to MenGoToMars.com right now, for a limited time, listeners of this program get 50% off for life, plus free shipping AND 3 free gifts. QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. CARGURUS CarGurus is the #1 rated car shopping app in Canada on the Apple App and Google Play store. They've got hundreds of thousands of cars from top-rated dealers, plus advanced search tools that let you zero in on exactly what you want. And you can set real-time alerts for price drops and new listings — so you never miss a great deal. Buy your next car today with CarGurus at cargurus dot ca. Go to cargurus dot ca to make sure your big deal is the best deal. BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive $5 OFF any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/
In this Episode of the Secure Your Retirement Podcast, Radon and Murs discuss the emotional side of the transition into retirement with clients Vid and Nupam Desai. Vid recently took early retirement after six years as chief information officer at the FDA, capping a 40-year career in pharmaceuticals, clinical research and medical devices. Nupam is still leading her team at Lenovo and planning her own retirement over the next couple of years. The four of them talk about learning to live together again, getting comfortable spending money you spent decades saving, and the travel, hobbies and giving back the Desais are planning for the years ahead.Listen in to learn about why even the most capable do-it-yourself planners reach a point where handing off taxes and investments brings relief, how seeing a plan on paper helps the logical and emotional sides of retirement catch up with each other, and what couples can expect when one spouse retires first.In this episode, find out:Why Vid calls holding on to his own finances and taxes for too long one of his biggest retirement lessons.How seeing their plan on paper helped the Desais start feeling confident about spending.What changes at home when one spouse retires and the other keeps working.Why Nupam is staying at Lenovo long enough to set her team up to succeed.How the Desais picture their first five to ten years of retirement, from six-week stays abroad to community service and the Peace Corps.Tweetable Quotes:"While we are financial advisors in this wealth management space, a lot of times what we are is a thought partner."Murs Tariq"A lot of times when people come to us, it's emotional. It's an emotional hurdle."Radon StancilResources:If you are in or nearing retirement and you want to gain clarity on what questions you should be asking, learn what the biggest retirement myths are, and identify what you can do to achieve peace of mind for your retirement, get started today by requesting our complimentary video course, Four Steps to Secure Your Retirement!To access the course, simply visit POMWealth.net/podcast.
© 2020-2026 Ivy Podcast Discovery LLC
